Cargando…
Use of Preclinical Models to Improve Treatment of Retinoblastoma
Dyer and colleagues examine the most promising preclinical models that recapitulate the molecular, genetic, and cellular features of retinoblastoma.
Autores principales: | Dyer, Michael A, Rodriguez-Galindo, Carlos, Wilson, Matthew W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1261510/ https://www.ncbi.nlm.nih.gov/pubmed/16231976 http://dx.doi.org/10.1371/journal.pmed.0020332 |
Ejemplares similares
-
Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models
por: Martínez-Pérez, Carlos, et al.
Publicado: (2016) -
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017) -
Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastoma
por: Taylor, Jessica T, et al.
Publicado: (2020) -
Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014) -
Assessment of Retinoblastoma Capacity in the Middle East, North Africa, and West Asia Region
por: Burges, Michala, et al.
Publicado: (2020)